Full-Time
Detects low-abundance biomarkers with qPCR assays
$115k/yr
Burlington, MA, USA
Remote
| , |
Spear Bio develops highly sensitive biomarker detection technology that can identify disease indicators even when present at very low levels, including single-digit protein counts. It uses a proprietary 2-factor authentication detection method with sub-microliter samples, enabling minimally invasive collection and testing on non-proprietary qPCR instruments for easy automation. The platform is designed to integrate into existing lab workflows, offering open-system compatibility and scalable testing for large groups. The goal is to provide labs and healthcare providers with precise, scalable biomarker detection to support broad screening and diagnostics.
Company Size
11-50
Company Stage
Series A
Total Funding
$52.3M
Headquarters
Woburn, Massachusetts
Founded
2021
Help us improve and share your feedback! Did you find this helpful?
People at Spear Bio who can refer or advise you
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Remote Work Options
401(k) Retirement Plan
Stock Options
Company Equity
Wellness Program
Mental Health Support
Conference Attendance Budget
Professional Development Budget
Phone/Internet Stipend
Home Office Stipend
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Tuition Reimbursement
Professional Certification Support
Meal Benefits
Commuter Benefits
Childcare Support
Elder Care Support
Pet Insurance
Sabbatical Leave
Paid Holidays
Relocation Assistance
Performance Bonus
Profit Sharing
Employee Stock Purchase Plan
Training Programs
Mentorship Program
Education allowance
Legal Services
Employee Discounts
Company Social Events
Spear Bio introduces new ultra-sensitive neurodegenerative assays and expands direct access at AD/PD 2026. Published: 09 Apr 2026 Spear Bio is an innovator in ultrasensitive protein biomarker detection. International Conference on Alzheimer's & Parkinson's Diseases (AD/PD 2026) last week. The product coincides with the company's newly established direct-to-customer operation in North America and Europe, which becomes an important step that will streamline access to its technology for laboratories investigating neurodegenerative proteinopathies. First released SPEAR UltraDetect BD-pTau 217 Assay early adopters in the last month, remains the only brain-derived pTau 217 test to deliver 100% quantifiability in both healthy and diseased plasma samples. Operating in a homogeneous, wash-free format and requiring just 1 μL of diluted plasma, the assay achieves a functional lower limit of quantification of 25 fg/mL and an average intra-plate CV of 5.7%. These allow researchers and investigators to detect Alzheimer 's-related tau changes at the preclinical stage while preserving precious sample volume for longitudinal studies. According to Towards Healthcare, the qPCR instruments market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 7.41 billion in 2026 to approximately USD 15.95 billion by 2035, representing a compound annual growth rate (CAGR) of 8.9% from 2026 to 2035. Growth is driven by rising demand in clinical and research settings with the adoption of molecular diagnostics, which include multiplexing capabilities and automation of the digital health ecosystem, and enhance workflow efficiency. Founder and Chief Executive Officer of Spear Bio, Feng Xuan, said Its goal is to place the most sensitive protein biomarker tools in the hands of scientists tackling complex neurodegenerative diseases, empowering researchers to generate higher-quality data by expanding its assay portfolio and transitioning to direct customer engagement with greater efficiency and accelerating from discovery to clinical impact. About Spear Bio. Spear Bio, headquartered in Woburn, Massachusetts, is a biotechnology company pioneering wash-free ultrasensitive immunoassay technology. This platform delivers attomolar sensitivity from 1 μL of diluted sample and superior specificity of a homogeneous, wash-free format with readout on standard qPCR instruments. It is built on an ultra-performance approach that integrates sensitivity, specificity, precision, and assay robustness. Spear Bio also enables researchers and clinicians to reveal true biology with confidence. A recent report by Towards Healthcare highlights that the qPCR instruments market is witnessing growth due to widespread application of qPCR instruments in clinical diagnostics, genomic research, and oncology, with advanced automated and multiplexing capabilities with high throughput and real-time technology.
Spear Bio unveiled three new ultrasensitive neurodegenerative immunoassays at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD 2026), whilst launching direct-to-customer operations in North America and Europe. The Massachusetts-based company introduced brain-derived p-Tau 217, α-synuclein and phospho-Ser129-α-synuclein assays. The BD-pTau 217 test, released to early adopters last month, is the only brain-derived pTau 217 assay achieving 100% quantifiability in healthy and diseased plasma samples, requiring just 1 µL of diluted plasma. The new α-synuclein assays target Parkinson's disease and related synucleinopathies, quantifying monomeric and oligomeric synuclein species at low-femtogram concentrations using standard qPCR instruments. Founded in 2021, Spear Bio has raised undisclosed funding from investors to develop its wash-free ultrasensitive immunoassay technology.
Global Alzheimer's Platform Foundation announces strategic collaboration and partnership with Spear Bio for the transformative Bio-Hermes-002 study. Spear Bio joins collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias. WASHINGTON, Jan. 12, 2026 (GLOBE NEWSWIRE) - The Global Alzheimer's Platform Foundation(R)(GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive immunoassay technology, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities to generate data that may help predict, detect and diagnose Alzheimer's disease and related dementias. The Bio-Hermes-002 study collects data reflecting the performance of each biomarker in the study, or combination of biomarkers, to assess, diagnose or predict the presence of a variety of pathologies associated with Alzheimer's Disease and related dementias including amyloid and tau in the brain - hallmark characteristics of Alzheimer's disease. In Bio-Hermes-002, Spear Bio will provide results of blood-based biomarker analysis using its SPEAR UltraDetect(TM) assay platform that offers attomolar sensitivity from 1μL diluted sample and superior specificity of homogenous wash-free format in an effort to change the paradigm of early-stage disease diagnostics and monitoring for Bio-Hermes-002, building upon findings from Bio-Hermes-001. "We're proud to have Spear Bio as a valued partner in the Bio-Hermes-002 study," said John Dwyer, President of GAP. "Their technology platform is consistent with our goal to catalyze and scale early-stage disease diagnostics and monitoring, thereby transforming how we treat patients and conduct clinical trials for Alzheimer's and related dementias. By advancing biomarker detection, we hope to accelerate meaningful progress for individuals and families affected by these conditions."
WOBURN, Mass., July 25, 2025 /PRNewswire/ - Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, today announced the commercial launch of its SPEAR UltraDetect(TM) immunoassay solution.
Woburn, MA July 15, 2025 - Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation (NASDAQ: TECH), a global leading provider of innovative reagents, instruments, and solutions for life-science research and clinical diagnostics.